SMS Pharmaceuticals Ltd. is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities. What started off as a single facility single product manufacturing company in 1990 grew to be a multi location group having product list spreading across an array of therapeutic segments. SMS is currently a listed company having ever appreciating international and domestic customer base. Having six multi product facilities in operation, one under development, and two research centers, SMS has truly graduated in to big league with more than 600 employees working for it.

SMS Pharmaceuticals is an integrated pharma company with business presence in over 70 countries.

SMS is focused on API manufacturing and is the single largest producer of anti ulcer products and is renowned among the clientele for the excellent quality of product and customer service.

The company is diversifying into CRAMS by creating research and manufacturing facilities bettering the requirements of the regulatory markets to appeal to international clientele.

SMS is venturing into highly specialized oncology segment by building first of its kind dedicated oncology API and formulations manufacturing facility in Andhra Pradesh to target the niche market segments.

Merger of Sreenivasa Pharma Private Ltd with SMS Pharmaceuticals Ltd has given a new boost to the company, SMS Pharma has also completed the takeover of Plant Organics.

Recently SMS has established new state of art corporate research center with ultramodern facilities encompassing the whole gamut of research activity viz. from product conception to development, scaling up and DMF preparation. This is supported by well equipped analytical wing and a fully functional pilot plant. This new facility will enhance our existing offerings from a contract research and custom synthesis point of view.

R&D at SMS drives the company’s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.

SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.

Product range of the company includes:

 * API and Intermediates
 * Cytotoxic Solid Dose, Sterile Cytotoxic Liquid, and Lyophilized Products
 * Bio Products
 * Inorganic Products
 * Nutraceuticals

SMS Pharmaceuticals Ltd.

Zota Health Care Ltd.

Lincoln Pharmaceuticals Ltd.

Bliss GVS Pharma Ltd.

Kopran Ltd.

Jagsonpal Pharmaceuticals Ltd.

Themis Medicare Ltd.

Panacea Biotec Ltd.

Windlas Biotech Ltd.

MEDICO

Nectar Lifesciences Ltd.

Sakar Healthcare Ltd.

Ind-Swift Laboratories Ltd.

Lyka Labs Ltd.

Albert David Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	693 Cr		EPS	1.2		High	86.65
Stock P/E	65.7		Net Profit Margin	0.5		Low	84.4

Open Price	82.5	Volume	1
Prev. Close	82.5

SMSPHARMA